LUBBOCK, Texas, Jan. 6, 2015 /PRNewswire/ -- Kiromic, LLC, a clinical-stage biopharmaceutical company focused on developing oral and injectable vaccines and therapeutics for cancer and other diseases, today announced that it will be presenting at two upcoming investor conferences in January. Scott Dahlbeck, M.D., Pharm.D., chief executive officer of Kiromic, will provide an overview of the company and highlight select programs from its clinical and preclinical development pipeline. The scheduled presentations are as follows:
- The 8th Annual OneMedForum, January 12, 2015, 2:45 p.m. PT, at the San Francisco Marriot Marquis
- The 7th Annual Biotech Showcase, January 14, 2015, 4:45 p.m. PT, at the Parc 55 Wyndham San Francisco
About Kiromic
Kiromic is a clinical-stage immuno-oncology focused biopharmaceutical company with discovery and development programs across multiple technology platforms, including dendritic cell based cancer vaccines, oral vaccine immunotherapy, carbohydrate-binding protein inhibition, and gene therapy. The company's lead immunotherapy programs include a CTA targeted dendritic cell vaccine in Phase 1/2 development for multiple tumor types and an NIH supported CTA targeted oral cancer vaccine in preclinical development for ovarian and other cancers. The company's other product candidates include a galectin inhibitor for multiple myeloma as well as an adeno-associated virus based gene therapy for select cardiovascular conditions.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/kiromic-to-present-at-upcoming-investor-conferences-in-january-300016256.html
SOURCE Kiromic, LLC
